Elekta AB reported a 2% decline in net sales in constant exchange rates for the first quarter of fiscal 2027, with Solutions sales down 9% and Service sales up 5%, while adjusted gross margin improved to 42.6% from 37% a year earlier, including a SEK53 million positive impact from US tariff refunds. Adjusted EBIT margin reached 11.2%, and net income amounted to SEK261 million, with adjusted earnings per share of SEK0.69. Free cash flow improved by SEK154 million year-on-year to negative SEK266 million, and the book-to-bill ratio was 1.11 with order growth of 3%. The company reconfirmed its full-year outlook of 2% to 4% net sales growth in constant currency and an adjusted EBIT margin of 12.5% to 13.5%, despite headwinds from a stronger Swedish krona and higher tungsten prices. CEO Jakob Just-Bomholt noted solid double-digit order growth in the US following the Elekta Evo launch, while sales in China declined due to weak order intake from previous years, though the company expects solid revenue growth in the second quarter.
Elekta AB ser. BQ1 net sales declined 2% and Solutions sales fell 9%, though margins improved.
China Grand Pharmaceutical and Healthcare Holdings Ltd
Shanghai Henlius Biotech Inc
